首页> 外文期刊>Recent patents on cardiovascular drug discovery. >Combining stem cells and tissue engineering in cardiovascular repair-a step forward to derivation of novel implants with enhanced function and self-renewal characteristics
【24h】

Combining stem cells and tissue engineering in cardiovascular repair-a step forward to derivation of novel implants with enhanced function and self-renewal characteristics

机译:将干细胞与组织工程结合起来进行心血管修复-迈出具有增强功能和自我更新特性的新型植入物的一步

获取原文
获取原文并翻译 | 示例
           

摘要

The use of stem and progenitor cells in cardiovascular therapy has been proposed as a feasible option to promote repair of tissue damage by ischemia, or to devise definitive artificial tissue replacements (valves, vessels, myocardium) to be surgically implanted in patients. Whereas in other medical branches such as dermatology and ophthalmology the use of ex vivo grown tissues is already accessible to a large degree, the use of bio-artificial implants in cardiovascular surgery is still marginal. This represents a major limitation in cardiovascular medicine at present. In fact, the limited durability and the lack of full compatibility of current implantable devices or tissues prevent a long-term resolution of symptoms and often require re-intervention thereby further increasing the economic burden of the cardiovascular disease. Stem cell technology can be of help to derive tissues with improved physiologic function and permanent durability. Specifically, the intrinsic ability of stem cells to produce tissue-specific "niches", where immature cells are perpetuated while differentiated progenitors are continuously produced, makes them an ideal resource for bioengineering approaches. Furthermore, recent advancements in biocompatible material science, designing of complex artificial scaffolds and generation of animal or human-derived natural substrates have made it feasible to have ex vivo reproduction of complex cellenvironment interactions - a process necessary to improve stem cells biological activity. This review focuses on current understanding of cardiovascular stem cell biology as well as tissue engineering and explores their interdisciplinary approach. By reviewing the relevant recent patents which have enabled this field to advance, it concentrates on various design substrates and scaffolds that grow stem cells in order to materialize the production of cardiovascular implants with enhanced functional and self-renewal characteristics.
机译:已经提出在心血管疗法中使用干细胞和祖细胞是一种可行的选择,以促进通过缺血修复组织损伤,或设计出最终的人工组织替代物(瓣膜,血管,心肌),以人工方式植入患者体内。在皮肤病和眼科等其他医学领域中,离体生长组织的使用已经在很大程度上可以实现,而生物人工植入物在心血管外科中的使用仍然很少。这代表了目前心血管医学的主要局限性。实际上,当前的可植入装置或组织的有限的耐用性和缺乏完全的兼容性阻止了症状的长期解决,并且常常需要重新干预,从而进一步增加了心血管疾病的经济负担。干细胞技术可以帮助获得具有改善的生理功能和持久耐用性的组织。具体而言,干细胞产生组织特异性“小生境”的内在能力(其中不成熟细胞得以持续而分化祖细胞不断产生)使它们成为生物工程方法的理想资源。此外,生物相容性材料科学的最新进展,复杂的人工支架的设计以及动物或人类来源的天然底物的产生,使得离体繁殖复杂的细胞环境相互作用成为可能,这是改善干细胞生物学活性的过程。这篇综述侧重于对心血管干细胞生物学以及组织工程学的当前理解,并探讨了它们的跨学科方法。通过审查使该领域得以发展的相关最新专利,它集中于生长干细胞的各种设计基质和支架,以实现具有增强的功能和自我更新特性的心血管植入物的生产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号